Alternative splicing coupled with transcript degradation modulates OAS1g antiviral activity

  1. David Baltimore1
  1. 1Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, California 91125, USA
  2. 2Center of Systems Medicine, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100005, China
  3. 3Suzhou Institute of Systems Medicine, Suzhou 215123, China
  4. 4Center for Systems Immunology, University of Pittsburgh, Pittsburgh, Pennsylvania 15261, USA
  5. 5Department of Immunology, University of Pittsburgh, Pittsburgh, Pennsylvania 15261, USA
  1. Corresponding author: baltimo{at}caltech.edu

Abstract

At the heart of an innate immune response lies a tightly regulated gene expression program. This precise regulation is crucial because small changes can shift the balance from protective to destructive immunity. Here we identify a frequently used alternative splice site in the gene oligoadenylate synthetase 1g (Oas1g), a key component of the 2–5A antiviral system. Usage of this splice site leads to the generation of a transcript subject to decay, and removal of the site leads to increased expression of Oas1g and an improved antiviral response. However, removal of the splice site also leads to an increase in apoptotic cell death, suggesting this splicing event exists as a compromise between the pathogen protective benefits and collateral damage associated with OAS1g activity. Across the innate immune response, we show that a multitude of alternative splicing events predicted to lead to decay exist, and thus have the potential to play a significant role in the regulation of gene expression in innate immunity.

Keywords

  • Received October 29, 2019.
  • Accepted November 13, 2019.

This article is distributed exclusively by the RNA Society for the first 12 months after the full-issue publication date (see http://rnajournal.cshlp.org/site/misc/terms.xhtml). After 12 months, it is available under a Creative Commons License (Attribution-NonCommercial 4.0 International), as described at http://creativecommons.org/licenses/by-nc/4.0/.

| Table of Contents